uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Intranasal insulin in Alzheimer's disease: Food for thought
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Functional Pharmacology.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Functional Pharmacology.ORCID iD: 0000-0001-7112-0921
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience, Functional Pharmacology.ORCID iD: 000-0002-8911-4068
2017 (English)In: Neuropharmacology, ISSN 0028-3908, E-ISSN 1873-7064, article id S0028-3908(17)30566-XArticle in journal (Refereed) Epub ahead of print
Abstract [en]

Accumulating evidence suggests that disrupted brain insulin signaling promotes the development and progression of Alzheimer's disease (AD), driving clinicians to target this circuitry. While both traditional and more modern antidiabetics show promise in combating insulin resistance, intranasal insulin appears to be the most efficient method of boosting brain insulin. Furthermore, intranasal delivery elegantly avoids adverse effects from peripheral insulin administration. However, there remain significant open questions regarding intranasal insulin's efficacy, safety, and potential as an adjunct or mono-therapy. Thus, this review aims to critically evaluate the present evidence and future potential of intranasal insulin as a meaningful treatment for AD.

Place, publisher, year, edition, pages
2017. article id S0028-3908(17)30566-X
Keywords [en]
Alzheimer's disease, Brain insulin resistance, Cognition, Intranasal insulin, Neurodegeneration
National Category
Neurosciences
Identifiers
URN: urn:nbn:se:uu:diva-342186DOI: 10.1016/j.neuropharm.2017.11.037PubMedID: 29180222OAI: oai:DiVA.org:uu-342186DiVA, id: diva2:1183856
Available from: 2018-02-19 Created: 2018-02-19 Last updated: 2018-03-22Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Chapman, Colin DSchiöth, Helgi B.Benedict, Christian

Search in DiVA

By author/editor
Chapman, Colin DSchiöth, Helgi B.Benedict, Christian
By organisation
Functional Pharmacology
In the same journal
Neuropharmacology
Neurosciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 3 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf